Continued steady growth for Bio-Works in first quarter – on the way to breakeven
Today, Bio-Works Technologies AB reported its sales development for the first quarter of 2023. Bio-Works revenues increased by +27% versus the prior year period. Total sales for the first quarter amounted to 7.6 MSEK. At the same time, order intake increased by 43% to 11.0 MSEK. The strongest growth was seen in order backlog which increased 210% during the period to 26.0 MSEK.Market conditions remain favorable despite a general slowdown in the biopharma-segment as result of economic uncertainties, inflation and increasing interest rates which have had a negative effect on access to capital—